Market revenue in 2023 | USD 74.4 million |
Market revenue in 2030 | USD 138.3 million |
Growth rate | 9.3% (CAGR from 2023 to 2030) |
Largest segment | Functional genomics |
Fastest growing segment | Pathway Analysis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Functional Genomics, Epigenomics, Pathway Analysis, Biomarker Discovery |
Key market players worldwide | Agilent Technologies Inc, Bio-Rad Laboratories Inc, Danaher Corp, Eppendorf, Eurofins Scientific SE, Roche Holding AG ADR, GE Aerospace, Illumina Inc, Myriad Genetics Inc, Oxford Nanopore Technologies PLC, Pacific Biosciences of California Inc, Qiagen NV, Quest Diagnostics Inc, Thermo Fisher Scientific Inc, 23andMe Holding Co Class A |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to genomics market will help companies and investors design strategic landscapes.
Functional genomics was the largest segment with a revenue share of 31.59% in 2023. Horizon Databook has segmented the Thailand genomics market based on functional genomics, epigenomics, pathway analysis, biomarker discovery covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing investments by the Thai government along with the growing market are responsible for the country becoming a hub for precision medicine and genomic projects. Some of the projects undertaken by the Thailand government are Genomics Thailand Initiative launched in 2019, National Biobank of Thailand (NBT) established in 2019, and the Southeast Asian genome-sequencing project.
Over the past few years, the CDC and Ministry of Public Health in Thailand are working on developing intervention strategies to fight against high-risk diseases. The prevalence of cancer has increased in the country, accounting for 19% of the overall deaths, followed by 12% of deaths due to ischemic heart disease, and 10% due to stroke.
Moreover, increase in the incidence of infectious diseases such as hepatitis, diarrhea, dengue fever, malaria, Japanese encephalitis, HIV, leptospirosis, and rabies is expected to fuel the demand for genome sequencing technologies for proper diagnosis & treatment.
Horizon Databook provides a detailed overview of country-level data and insights on the Thailand genomics market , including forecasts for subscribers. This country databook contains high-level insights into Thailand genomics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account